RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics, Inc. today announced favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a double-blind, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback